Pharmacological Evaluation of NOP Receptor Non-Peptide Agonists - G protein vs Arrestin Bias Evaluation

The nociceptin/orphanin FQ peptide (NOP) receptor, the fourth member of the opioid receptor family, regulates physiological processes such as pain modulation, emotional behavior, substance abuse, and vascular function. The receptor’s ability to activate specific intracellular pathways through selective coupling to G proteins (guanine nucleotide-binding proteins) or β-arrestins underlies biased agonism in opioid pharmacology. This study aimed to pharmacologically characterize a novel, non-peptidic, selective NOP receptor partial agonist, with a focus on β-arrestin2 recruitment. Our experiments involving HEK293 (human embryonic kidney 293) and CHO (Chinese hamster ovary) cell lines permanently expressing the NOP receptor and β-arrestin2 constructs demonstrated ligand-dependent variations in efficacy and kinetics of recruitment for five different ligands. Bioluminescence resonance energy transfer (BRET) and calcium mobilization assays identified functionally selective signaling patterns, confirming distinct differences in β-arrestin2 interaction and receptor signaling profiles among the ligands. These findings provide evidence for biased agonism at the NOP receptor. Overall, this study enhances the understanding of NOP receptor pharmacology and supports the development of novel NOP-targeted compounds with improved therapeutic potential. Such advances could lead to more effective treatments with fewer side effects for conditions like pain and anxiety, highlighting a promising direction for future therapeutic interventions.